Dr Chi on Potential Prognostic Markers for Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC

"Honestly, I expected to see that patients with higher PSMA PET standard uptake value [SUV] mean would do better with lutetium, and patients with lower SUV mean would do better with docetaxel. However, we did not see that."

Kim Nguyen Chi, MD, FRCPC, a medical oncologist at Vancouver Cancer Centre and Vancouver Prostate Centre, chief medical officer and Shrum Chair in Prostate Cancer Research for BC Cancer – Vancouver, and a professor in the faculty of Health Sciences at Simon Fraser University, discussed the relationship between prostate specific-membrane antigen (PSMA) PET standard uptake value (SUV) and circulating tumor (ctDNA) positivity and outcomes with lutetium Lu 177 vipivotide tetraxetan (Pluvicto; formerly 177Lu-PSMA-617) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) from the phase 2 Canadian Cancer Trials Group PR21 study (NCT04663997).